Welcome to Prestigio Registry platform

Publication
International Journal of Antimicrobial Agents
| July 2024

Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry

T.Clemente, S.Diotallevi, R.Lolatto, R.Gagliardini, A.Giacomelli, M.Fiscon, M.Ferrara, A.Cervo, L.Calza, F.Maggiolo, S.Rusconi, M.M.Santoro, A.Castagna, V.Spagnuolo; PRESTIGIO Study Group

Publication
BMJ Open
| February 2024

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

T.Clemente, L.Galli, R.Lolatto, R.Gagliardini, F.Lagi, M.Ferrara, A.M.Cattelan, E.Focà, A.Di Biagio, A.Cervo, L.Calza, F. Maggiolo, G.Marchetti, G.Cenderello, S.Rusconi, M.Zazzi, M.M.Santoro, V.Spagnuolo, A.Castagna; PRESTIGIO Study Group

Publication
International Journal of Antimicrobial Agents
| January 2023

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry

F.Saladini, F.Giammarino, F.Maggiolo, M.Ferrara, G.Cenderello, B.M.Celesia, F.Martellotta, V.Spagnuolo, G.M.Corbelli, N.Gianotti, M.M.Santoro, S.Rusconi, M.Zazzi, A.Castagna, PRESTIGIO Study Group et al.

Publication
Journal of infection
| March 2022

Inflammation burden score in multidrug-resistant HIV-1 infection

T.Clemente, R.Caccia, L.Galli, A.Galli, A.Poli, G.Marchetti, A.Bandera, M.Zazzi, M.M.Santoro, P.Cinque, A.Castagna, V.Spagnuolo, PRESTIGIO Study Group et al.

Publication
Pharmacological Research
| February 2022

Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects

S.Rusconi, F.Saladini, M.C.Bellocchi, L.Galli, R.Gagliardini, L.Gazzola, D.Francisci, F.Vichi, E.Focà, M.Zazzi, M.M.Santoro, A.Gabrieli, A.Castagna, PRESTIGIO Registry study group et al.

Publication
International Journal of Antimicrobial Agents
| January 2022

Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV

D.Armenia, M.M.Santoro, M.C.Bellocchi, L.Carioti, L.Galli, A.Galli, R.Scutari, E.Salsi, C.Mussini, G.Sterrantino, L.Calza, B.Rossetti, M.Zazzi, A.Castagna, PRESTIGIO Registry Study Group et al.

Publication
Open Forum Infectious Diseases
| September 2020

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry

L.Galli, M.R.Parisi, A.Poli, M.Menozzi, M.Fiscon, E.Garlassi, D.Francisci, A.Di Biagio, G.Sterrantino, C.Fornabaio, A.Degli Antoni, G.Angarano, F.M.Fusco, A.D'Arminio Monforte, G.M.Corbelli, M.M.Santoro, M.Zazzi, A.Castagna, PRESTIGIO Study Group et al.

Publication
Journal of Antimicrobial Chemotherapy
| September 2020

In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients

F.Saladini, A.Giannini, F.Giammarino, F.Maggiolo, F.Vichi, G.M.Corbelli, A.Galli, A.Bigoloni, A.Poli, M.M.Santoro, M.Zazzi, A.Castagna et al.

Publication
Journal of Acquired Immune Deficiency Syndromes
| August 2020

Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry

D.Canetti, L.Galli, N.Gianotti, A.Celotti, L.Calza, R.Gagliardini, S.Rusconi, S.Modica, G.Cenderello, M.Ferrara, M.M.Santoro, M.Zazzi, A.Castagna, PRESTIGIO Study Group et al.

Publication
Journal of Antimicrobial Chemotherapy
| January 2018

Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

A.Castagna, M.Ferrara, L.Galli, L.Comi, G.Sterrantino, G.Cenderello, M.Zaccarelli, E.Focà, A.Roncadori, A.Lazzarin, PRESTIGIO Study Group et al.